Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Veracyte, Inc.NASDAQ: VCYT
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $4.84M fell 11.9% year over year, behind the -9.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 10.9% from the prior quarter. Over 3 fiscal years it compounded at -6.2% a year.
Context
- Depreciation & amortization amounted to 4.1% of revenue in FY2025, down 1.1 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -11.9% toward the trailing-twelve-month pace of -9.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 21.42M USD
- Year-over-year change
- -8.7%
- 4-year CAGR
- +2.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.42M | -8.7% |
| FY2024 | 2024-12-31 | 23.46M | -13.7% |
| FY2023 | 2023-12-31 | 27.19M | +4.9% |
| FY2022 | 2022-12-31 | 25.93M | +32.3% |
| FY2021 | 2021-12-31 | 19.59M | — |
Depreciation & Amortization vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's LTM Jun 2026 depreciation & amortization of $20.83M is the 5th largest of the 10 companies compared; the peer median is $14.94M.
- Its year-over-year change of -9.4% is the 7th highest of 9, against a peer median of -5.1%.
- Depreciation & amortization amounts to 3.7% of revenue for VCYT, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
| LTM Sep 2026 | $39.23M | -2.3% | +3.4% | 3.1% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $26.88M | +15.1% | -24.8% | 5.9% |
| LTM Jun 2026 | $20.83M | -9.4% | -6.2% | 3.7% | |
| LTM Mar 2026 | $14.94M | -64.8% | +57.0% | 4.4% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.3M | — | — | 3.1% |
| LTM Mar 2026 | $9.83M | -8.1% | +6.0% | 15.2% | |
| LTM Mar 2026 | $5.58M | +0.8% | -1.4% | 5.8% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| Peer median (excluding VCYT) | $14.94M | -5.1% | -0.1% | 5.9% | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.56M) | (36.56M) | (74.4M) | 24.14M | 66.35M |
| Depreciation & Amortization | 19.59M | 25.93M | 27.19M | 23.46M | 21.42M |
| Deferred Income Tax | (6.26M) | 133K | (3.84M) | (233K) | (581K) |
| Stock-Based Compensation | 22.52M | 26.73M | 33.14M | 36.25M | 43.6M |
| Change in Working Capital | 4.22M | (16.38M) | (3.7M) | (20.97M) | (2.3M) |
| Accounts Receivables | (8.57M) | (4.5M) | 3.89M | (6.41M) | (708K) |
| Inventory | (1.46M) | (3.01M) | (1.69M) | (5.87M) | (2.86M) |
| Accounts Payables | 5.16M | 152K | (134K) | (4.31M) | (1.04M) |
| Other Working Capital | 9.1M | (9.03M) | (5.75M) | (4.38M) | 2.31M |
| Other Non-Cash Items | 3.87M | 7.68M | 65.83M | 12.45M | 7.82M |
| Operating Cash Flow | (31.62M) | 7.54M | 44.22M | 75.1M | 136.31M |
| Capital Expenditures | (5.38M) | (8.55M) | (9.96M) | (11.29M) | (9.68M) |
| Acquisitions (Net) | (736.83M) | 0 | 0 | 5.01M | (2.85M) |
| Purchases of Investments | 162.42M | (33.52M) | (19.7M) | (50M) | (150M) |
| Sales of Investments | 3M | 12.68M | 44.77M | 0 | 153.31M |
| Other Investing Activities | (162.42M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (739.21M) | (29.39M) | 15.11M | (56.28M) | (9.21M) |
| Debt Repayment | 0 | (1.28M) | 0 | 0 | 0 |
| Common Stock Issued | 593.82M | 0 | 0 | 19.99M | 14.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.5M | 4.78M | 2.84M | (15.09M) | (18.3M) |
| Financing Cash Flow | 596.32M | 3.49M | 2.84M | 4.9M | (4.22M) |
| Effect of Forex Changes | (1.51M) | (592K) | 163K | (424K) | 615K |
| Net Change in Cash | (176.02M) | (18.95M) | 62.33M | 23.3M | 123.6M |
| Free Cash Flow | (37M) | (1.01M) | 34.26M | 63.81M | 126.63M |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.